Trade-Ideas LLC identified

Pfizer

(

PFE

) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Pfizer as such a stock due to the following factors:

  • PFE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $580.9 million.
  • PFE is up 2.7% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PFE with the Ticky from Trade-Ideas. See the FREE profile for PFE NOW at Trade-Ideas

More details on PFE:

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The stock currently has a dividend yield of 3.3%. PFE has a PE ratio of 16. Currently there are 9 analysts that rate Pfizer a buy, no analysts rate it a sell, and 6 rate it a hold.

The average volume for Pfizer has been 24.6 million shares per day over the past 30 days. Pfizer has a market cap of $223.5 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.95 and a short float of 0.8% with 3.11 days to cover. Shares are up 13.6% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Pfizer as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, increase in net income, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the ratings report include:

  • PFE's revenue growth has slightly outpaced the industry average of 14.4%. Since the same quarter one year prior, revenues rose by 19.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 26.9% when compared to the same quarter one year prior, rising from $2,376.00 million to $3,016.00 million.
  • Net operating cash flow has significantly increased by 141.02% to $1,651.00 million when compared to the same quarter last year. In addition, PFIZER INC has also vastly surpassed the industry average cash flow growth rate of -54.52%.
  • The debt-to-equity ratio is somewhat low, currently at 0.62, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.99 is somewhat weak and could be cause for future problems.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.